Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study
Matteo Ruggeri(Horta (Italy)), Biagio Di Iorio(Ospedale Civile di Voghera), Cynthia Bell(World Health Organization - Pakistan), Donald A. Molony(The University of Texas Health Science Center at Houston), Antonio Bellasi, Filippo Cipriani(Sanofi (Italy)), Domenico Russo(Federico II University Hospital)
Cited by 18
Related Papers
Early detection of kidney disease in community settings: the kidney early evaluation program (KEEP)
|American Journal of Kidney Diseases|2003|245
Left Ventricular Hypertrophy in Hypertensive Adolescents
|Hypertension|2007|219
Prevalence of Hypertension in Children
|Hypertension|2018|210
Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results of an Open-Label 24-Month Randomized Clinical Trial
|American Journal of Kidney Diseases|2013|177
Race and Obesity in Adolescent Hypertension
|PEDIATRICS|2017|143